UPDATE: Jefferies Raises PT to $29 on Aegerion Pharmaceuticals on Juxtapid Approval Outlook
Posted on December 27, 2012 at 10:21 AM EST
Jefferies reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ) and raised its price target from $24 to $29. Jefferies commented, "Juxtapid (lomitapide) approval for HoFH is in-line (EU decision in mid-2013). AEGR is to provide details on its commercial plan (# of identified pts, WAC, etc) on